Poor
Not Aligned
Patient Risk:
Medium
Summary
The submitted claims cannot be validated against the provided FDA label excerpts because no label text was supplied for many factual assertions (e.g., Pfizer history, patent ownership/expiration, brand naming rationale, generic manufacturer specifics, international trade-name usage, monitoring program presence, and guideline-tightening statements). Only general safety/usage-risk label excerpts were provided, which are not sufficient to support or refute most claims.
Category Scores
Accurate Statements
Oxycodone is an opioid analgesic ingredient in PERCOCET and acetaminophen is an analgesic ingredient.
Label excerpts supplied include that PERCOCET contains oxycodone (Schedule II) and that acetaminophen has hepatotoxicity warnings (5 WARNINGS; 7 DRUG INTERACTIONS; 12 CLINICAL PHARMACOLOGY).
PERCOCET is indicated for management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
1 INDICATIONS AND USAGE: “PERCOCET is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.”
Unsupported Statements
Percocet is a brand name owned by Pfizer.
No supporting label text provided regarding corporate ownership/brand ownership.
Pfizer launched the first prescription product combining oxycodone with acetaminophen in 1984.
No label text provided addressing launch history or firstness.
The formulation was positioned as a ready-made, low-dose opioid suitable for acute and chronic pain that could be taken on an as-needed basis.
No label excerpt provided describing marketing positioning, “low-dose,” “acute and chronic,” or “as-needed basis” language.
Oxycodone treats moderate-to-severe pain.
No label excerpt provided stating that efficacy characterization.
Acetaminophen (paracetamol) is a non-opioid analgesic that reduces inflammation and fever.
No label excerpt provided stating anti-inflammatory/antipyretic effects.
The combination of oxycodone with acetaminophen delivers greater pain relief than either drug alone.
No label excerpt provided comparing efficacy vs. monotherapy.
The combination allows lower opioid doses, reducing the risk of some opioid-specific side effects.
No label excerpt provided that lower opioid dosing occurs or that specific side effects are reduced.
The name “Percocet” includes “acet,” referencing the acetaminophen component.
No label text provided discussing etymology.
Pfizer chose the name “Percocet” to highlight both ingredients in a single, memorable label.
No label text provided regarding naming rationale.
Percocet received FDA approval in 1984.
No label excerpt provided approval year.
Percocet was approved under the prescription drug classification for opioid analgesics.
While opioid classification is consistent with the label excerpt referencing oxycodone as Schedule II and opioid risks, no label excerpt provided the specific “prescription drug classification for opioid analgesics” phrasing or classification history.
Percocet approval was based on clinical trials demonstrating that the oxycodone/acetaminophen combination produced effective pain relief with an acceptable safety profile when used as directed.
No label excerpt provided clinical trial evidence or “as directed” summary.
Pfizer holds several patents related to the oxycodone/acetaminophen formulation, including composition-of-matter and method-of-use claims.
No label text provided addressing patents.
According to DrugPatentWatch, the patents related to Percocet expired in the early 2000s.
No label text provided addressing patent expiration; also cites an external source not present in supplied label excerpts.
The expiration of the original patents paved the way for generic manufacturers to produce the drug under the name “acetaminophen/oxycodone.”
No label text provided regarding generic entry timing/naming due to patent expiration.
In the U.S., once the original patents expired, the FDA approved multiple generic equivalents that list the ingredients separately rather than using the brand name.
No label text provided regarding FDA generic approvals or naming conventions.
Generic versions are sold by companies such as Teva and Mylan.
No label text provided naming generic manufacturers.
These generics offer the same therapeutic effect at a lower cost.
No label excerpt provided therapeutic equivalence vs. cost claims.
Other oxycodone/acetaminophen combinations include Percodan.
No label excerpt provided mentioning Percodan as another product.
Percodan is a trade name still used in some countries.
No label excerpt provided international trade-name usage.
In the U.S., once the original patents expired, the FDA approved multiple generic equivalents that list the ingredients separately rather than using the brand name.
No label excerpt provided regarding patent-expiration-linked approvals or specific generic naming.
In the U.S., non-opioid options (e.g., acetaminophen alone and ibuprofen) serve as alternatives.
No label excerpt provided listing ibuprofen or non-opioid alternative drugs.
In the U.S., prescription opioid monotherapies (e.g., oxycodone alone and hydrocodone/acetaminophen) serve as alternatives.
No label excerpt provided listing specific alternative opioids.
Authorities have tightened prescribing guidelines for opioid drugs including Percocet.
No label excerpt provided statements about guideline changes.
Percocet appears on prescription monitoring program lists.
No label excerpt provided about monitoring program lists.
Clinicians must adhere to federal and state limits on dosage and duration for Percocet.
No label excerpt provided specific legal requirements on dosage/duration by federal/state authorities.
Percocet remains a common first-line prescription for moderate to severe pain.
No label excerpt provided utilization frequency or “first-line” status.
Contradictions
Low
AI Statement
The formulation was positioned as a ready-made, low-dose opioid suitable for acute and chronic pain that could be taken on an as-needed basis.
Label Reference
1 INDICATIONS AND USAGE and 2 DOSAGE AND ADMINISTRATION provided do not support the specific positioning claims; however, no direct contradiction text was provided in the excerpts.
Important Omissions
Details on PERCOCET dosing limits and acetaminophen maximum (e.g., total daily acetaminophen should not exceed 4 grams) and dosing/titration risks are not addressed in the evaluated claims.
Importance:
Moderate
Boxed warning content regarding addiction, abuse, and misuse/overdose risk is not discussed in the evaluated claims, limiting label-alignment for safety-focused statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Most claims are historical/marketing/legal/third-party assertions not grounded in the provided label excerpts. Safety-relevant label content (addiction/respiratory depression/CYP3A4 interactions/acetaminophen hepatotoxicity and dosing limits) is not evaluated against claims, so potential risk from misalignment is increased primarily due to unvalidated safety and usage implications.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Large portion of claims are not supported by the supplied FDA label excerpts (corporate history, patent/legal timing, naming rationale, generic market details, guideline/monitoring assertions, efficacy comparisons vs. monotherapy). Only general indication language and ingredient identity are supported by the provided label text.
Suggested Improvement
Evaluate only claims that are directly supported by provided label sections (Indications/Usage, Dosage and Administration, Contraindications, Warnings/Precautions, Drug Interactions, Adverse Reactions). For factual history/patent/market/guideline assertions, do not treat them as label-aligned unless the label excerpts explicitly contain those facts.